Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Medincell S.a. Stock

Price
Target price
€14.44

€14.44

0.140%
0.02
0.140%
-
 
03.05.24 / Tradegate WKN: A2N6VA / Name: Medincell S.a. / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Medincell S.a. in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Medincell S.a. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Medincell S.a.

sharewise wants to provide you with the best news and tools for Medincell S.a., so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies: https://mms.businesswire.com/media/20191128005494/en/700687/5/MedinCell-Logo-notagline.jpg
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies


Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will

BusinessWire_EN 
0 16.04.24
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria: https://mms.businesswire.com/media/20191128005494/en/700687/5/MedinCell-Logo-notagline.jpg
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria


Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable

BusinessWire_EN 
0 08.04.24
MedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI): https://mms.businesswire.com/media/20191128005494/en/700687/5/MedinCell-Logo-notagline.jpg
MedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)


MedinCell (Paris:MEDCL):



Access here the complete press release



About UZEDY



During the Q4 2023 earnings call held today by Teva Pharmaceutical Industries Ltd., President and CEO Richard

BusinessWire_EN 
0 31.01.24
MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI): https://mms.businesswire.com/media/20191128005494/en/700687/5/MedinCell-Logo-notagline.jpg
MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)


Teva Pharmaceutical Industries Ltd. announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase 3 clinical trial of mdc-TJK

BusinessWire_EN 
0 09.01.24
MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749): https://mms.businesswire.com/media/20191128005494/en/700687/5/MedinCell-Logo-notagline.jpg
MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)


Regulatory News:



MedinCell (Paris:MEDCL):



In a joint press release announcing the financing agreement:




  • Richard Francis, President and CEO of Teva said: “Since launching Teva’s Pivot to

BusinessWire_EN 
0 13.11.23